Signos Pricing Analysis & Total Cost

How Signos Pricing Works

Signos uses a tiered subscription model where longer commitments reduce the per-month rate. The month-to-month option costs approximately $399, while a 12-month prepaid plan brings the price to roughly $199 per month. A 6-month plan falls between these at around $259 monthly. These prices include the CGM hardware, app access, and algorithm-based meal scoring.

The pricing structure mirrors other direct-to-consumer health subscriptions that front-load savings to reduce churn. One detail often missed: the CGM sensors themselves cost manufacturers between $50 and $75 per unit at wholesale 1, meaning a significant portion of the subscription fee covers software, data infrastructure, and margin rather than hardware. For context, a Dexcom G7 sensor retails around $89 without insurance, and each sensor lasts 10-14 days, requiring two per month.

Signos does not bill insurance. Because CGM use for weight management in non-diabetic individuals is considered off-label, no major payer covers this indication. The entire cost is out-of-pocket. A 2023 analysis in Diabetes Technology & Therapeutics noted that CGM cost remains the primary barrier to broader adoption in preventive metabolic health 2.

What Clinical Evidence Supports CGM for Weight Loss?

The evidence base for CGM-guided weight loss in people without diabetes is growing but still thin. A randomized trial published in JAMA Internal Medicine (N=116) found that CGM use combined with dietary counseling did not produce statistically significant additional weight loss compared to counseling alone over 12 months 3.

However, a smaller pilot study (N=53) in Nutrients showed that participants using real-time glucose feedback lost 3.4 kg more than controls over 16 weeks, primarily through reduced postprandial glycemic variability 4. The mechanism is behavioral: seeing glucose spikes after specific foods may reinforce avoidance of those foods.

Dr. Roy Taylor, professor of Medicine and Metabolism at Newcastle University, has stated: "Continuous glucose monitoring provides a feedback loop that some individuals find motivating, but it is not a substitute for caloric deficit. The technology measures one metabolic parameter among many that influence body weight" 5.

The American Diabetes Association's 2024 Standards of Care acknowledge CGM value for type 2 diabetes management but do not recommend it as a weight-loss tool for non-diabetic populations 6. This distinction matters for evaluating whether Signos pricing reflects clinical value or premium positioning for a consumer wellness product.

Total Cost Breakdown: Year One vs. Year Two

Year one on the 12-month plan costs approximately $2,388 all-in. This includes onboarding, two CGM sensors per month (24 total), unlimited app access, and a metabolic assessment. Some users report additional charges for provider consultations ranging from $50-$100 per session, though basic chat support is included.

Year two pricing depends on retention offers. Signos typically offers returning members a 10-15% discount, bringing the annual cost to roughly $2,030-$2,150. Without the discount, the renewal rate matches the original subscription tier. Over two years, the total investment ranges from $4,418 to $4,776 on the most economical plan.

For comparison, a 68-week course of semaglutide 2.4 mg (Wegovy) at list price costs approximately $16,942 but produced 14.9% mean body weight reduction in the STEP-1 trial (N=1,961) 7. With manufacturer coupons or insurance, many patients pay $0-$500 monthly. The weight-loss magnitude from pharmacotherapy far exceeds what behavioral interventions alone, including CGM-guided ones, typically achieve.

A 2022 meta-analysis in Obesity Reviews found that digital health interventions combining wearable sensors with app-based coaching produced mean weight loss of 2.3-4.1 kg over 12 months 8. At $2,388 annually for Signos, the cost-per-kilogram-lost could exceed $580-$1,038 based on these averages.

Signos vs. Alternatives: Price and Feature Comparison

Several competitors now occupy the CGM-for-weight-loss category. Levels Health charges approximately $199-$349 monthly with a similar sensor-plus-app model. Nutrisense prices at $225-$399 per month and includes dietitian consultations. January AI offers a lower-cost option at $149-$288 monthly using predictive glucose modeling that requires fewer sensor days.

The differentiation between these platforms is primarily algorithmic. Signos emphasizes its "glucose score" system that rates foods on a 1-10 scale based on individual glycemic response. Levels uses a "zone score" framework. Nutrisense pairs sensor data with human dietitian review. None of these algorithmic approaches have been validated in peer-reviewed head-to-head trials against each other.

Dr. Anne Peters, Professor of Clinical Medicine at USC Keck School of Medicine, noted in a 2023 commentary: "The consumer CGM market has outpaced the evidence. We have strong data for CGM in type 1 and type 2 diabetes, but extrapolating that benefit to metabolically healthy individuals seeking weight loss requires assumptions the literature does not yet support" 9.

One cost advantage Signos offers over some competitors: the subscription includes sensor hardware. Nutrisense, by contrast, has occasionally required separate sensor purchases during supply constraints, pushing effective monthly costs above $450 during those periods.

Is Signos Legitimate?

Signos is a registered business operating legally in the United States. The company partners with licensed healthcare providers who prescribe CGM sensors (a prescription is required for Dexcom and Libre devices). The app has FDA registration as a general wellness product, not as a medical device or treatment.

The distinction between "legitimate business" and "clinically validated intervention" matters here. Signos makes no FDA-cleared claims about weight loss. Its marketing frames glucose optimization as a path to better metabolic health and body composition, which is technically defensible but not equivalent to proven efficacy.

User reviews on Trustpilot and Reddit show a bimodal distribution: highly engaged users who already track nutrition closely report meaningful behavioral insights, while less engaged users often describe the sensors as "expensive glucose toys" that did not change their eating habits after the novelty wore off. A 2024 real-world analysis of CGM adherence in non-diabetic users found that 41% discontinued use within 90 days 10.

The Better Business Bureau lists Signos with an A rating. No major regulatory actions or FDA warning letters have been issued against the company as of May 2026. Customer complaints center primarily on billing disputes related to auto-renewal and difficulty canceling subscriptions.

Who Gets the Most Value from Signos?

The populations most likely to benefit from CGM feedback are those with prediabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%) and individuals with insulin resistance who may not yet carry a diabetes diagnosis. For these groups, real-time glucose data provides actionable information beyond what periodic lab work reveals.

The CDC estimates that 97.6 million American adults (38.0% of the adult population) have prediabetes, and 80% of them are unaware 11. For someone in this category, CGM data showing consistent postprandial glucose excursions above 140 mg/dL could motivate dietary changes before pharmacotherapy becomes necessary. A study in The Lancet Digital Health found that CGM-guided lifestyle intervention in prediabetic adults reduced HbA1c by 0.3% more than standard counseling over 6 months (P=0.02, N=172) 12.

For metabolically healthy individuals with normal glucose tolerance, the value proposition weakens considerably. Their glucose excursions are already well-regulated, and the CGM will mostly confirm that their pancreas functions properly. Spending $2,388 annually to repeatedly learn that oatmeal spikes glucose mildly while eggs do not offers diminishing returns after the first month.

Hidden Costs and Cancellation Considerations

Beyond the subscription fee, several ancillary costs emerge. Signos recommends (but does not require) a compatible smart scale ($50-$150) and offers premium "metabolic reset" coaching packages at $199-$499 per program. Shipping for sensor replacements is free on annual plans but may incur $9.99 charges on monthly subscriptions.

Cancellation requires contacting support; there is no self-service cancellation button in the app. Users on annual plans who cancel mid-term do not receive prorated refunds after the 30-day guarantee window. This structure is common in subscription wellness companies but catches some consumers off-guard.

The opportunity cost also deserves mention. At $199/month, a consumer could alternatively afford: a registered dietitian consultation twice monthly ($75-$150 each), a gym membership ($30-$80), and basic metabolic blood panels quarterly ($50-$150 per panel). This combination provides human expertise, exercise access, and objective lab data without a continuous sensor commitment. Whether Signos adds value beyond this depends entirely on how much the real-time feedback loop changes individual behavior.

The GLP-1 Comparison: Cost per Pound of Weight Lost

Framing Signos purely as a weight-loss investment invites comparison with GLP-1 receptor agonists. Tirzepatide 15 mg (Zepbound) produced 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) 13. At current out-of-pocket pricing of $550-$1,060 monthly without insurance, the cost-per-percent-body-weight-lost is approximately $186-$359 over the treatment period.

For Signos, assuming a generous 3-4% body weight reduction (based on digital health intervention meta-analyses), the cost-per-percent at $2,388 annually comes to $597-$796. The pharmacotherapy delivers roughly 5-6x more weight loss per dollar spent, though it carries different risk profiles including gastrointestinal side effects (reported in 44% of tirzepatide patients) and the need for ongoing use to maintain results 14.

This comparison is imperfect. Signos markets itself as a behavior-change tool, not a pharmaceutical. Some users want glucose insight rather than appetite suppression. The right choice depends on starting BMI, metabolic status, risk tolerance, and whether the individual's primary barrier is knowledge (what spikes my glucose?) versus physiology (persistent hunger signals).

When Signos Pricing Makes Sense Financially

A rational case for Signos investment exists in three scenarios. First: a newly diagnosed prediabetic who wants 3-6 months of data to inform dietary choices before considering metformin. The short-term data collection has concrete clinical value. Second: an athlete or performance-focused individual optimizing fueling strategy around training, where glucose timing affects workout quality. Third: someone who has already tried caloric restriction and pharmacotherapy without success and wants to test whether food-specific glycemic responses explain their plateau.

Outside these cases, the $2,388-$4,788 annual cost likely exceeds the marginal benefit for a metabolically healthy person seeking general weight management. The Diabetes Prevention Program trial demonstrated that structured lifestyle intervention (diet plus 150 minutes weekly exercise) reduced diabetes incidence by 58% without any wearable technology 15. That intervention cost approximately $1,400 per participant annually in 2002 dollars.

The bottom line on Signos pricing: it is a premium consumer product with legitimate technology but limited clinical validation for its primary marketed use case. Buyers should expect to pay $2,388+ annually, understand that insurance will not contribute, and recognize that the evidence for CGM-driven weight loss in healthy adults remains preliminary.